Using an in vivo pharmacological approach in an accelerated murine model of DMD, we observed that halting the enzymatic activity of C1r/s normalizes the expression of fibrotic genes in FAPs and improves the muscle condition. This evidence concerns the gene C1R and Duchenne muscular dystrophy.